ALT5 Sigma to Exhibit at iFX EXPO Dubai January 14-16, 2025

Rhea-AI Summary

ALT5 Sigma (NASDAQ:ALTS) has announced its participation in the upcoming iFX EXPO Dubai at the Dubai World Trade Centre from January 14-16, 2025. The company will showcase at booth #26, offering product demonstrations and solutions to over 7,000 expected attendees.

ALT5 Sigma, a fintech company listed on Nasdaq and part of the Russell Microcap Index, provides blockchain-powered technologies for digital assets. Through its subsidiary ALT5 Sigma Inc., the company operates two main platforms: ALT5 Pay, a cryptocurrency payment gateway, and ALT5 Prime, an electronic over-the-counter trading platform. The company processed over US$1.2 billion in cryptocurrency transactions in 2023.

The company also maintains biotech activities focused on developing solutions to address the opioid crisis, with drugs in clinical trials targeting pain management alternatives to addictive opioids.

Positive

• Processed over US$1.2 billion in cryptocurrency transactions in 2023
• Part of Russell Microcap Index
• Operates two established platforms: ALT5 Pay and ALT5 Prime

Negative

• None.

LAS VEGAS, NV / ACCESSWIRE / January 9, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced its participation in the upcoming iFX EXPO Dubai.

ALT5 will be exhibiting through the three days of the show at the Dubai World Trade Centre, providing product demonstrations, solutions and general information to many of the 7,000+ attendees starting January 14^th in booth #26.

iFX EXPO Dubai 2025 is the ultimate meeting place for brokers, affiliates, traders, investors, and tech- and service-providers who are looking to succeed in the MENA region.

"ALT5 continues to showcase at iFX tradeshows around the world because it is a very significant and important industry segment. By listening to and engaging with new and existing clients at iFX Dubai, ALT5 remains on the leading edge of innovation and technology. We finished 2024 with strong business momentum and look to continue that into the new year." said Vay Tham, CRO ALT5 Sigma Corporation.

About ALT5 Sigma

The Company is a unique Nasdaq-listed multidisciplinary organization with a focus on healthcare and fintech. The Company is one of the constituents of the Russell Microcap Index, as of June 28, 2024.

Launched in 2018, ALT5 Sigma Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma Inc., through its subsidiaries, offers two main platforms to its customers: "ALT5 Pay" and "ALT5 Prime". ALT5 Sigma Inc. processed over US$1.2 billion in cryptocurrency transactions in 2023.

ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency (s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.

Through its biotech activities, the Company is developing innovative, actionable solutions intended to help end the opioid crisis. The Company is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5's platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion. This press release also contains statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential", and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Contact Information

Investor Relations
ir@alt5sigma.com
1-800-400-2247

SOURCE: ALT5 Sigma Corp

View the original press release on accesswire.com

FAQ

How much in cryptocurrency transactions did ALT5 Sigma (ALTS) process in 2023?

ALT5 Sigma processed over US$1.2 billion in cryptocurrency transactions during 2023.

When and where is ALT5 Sigma (ALTS) exhibiting at iFX EXPO Dubai 2025?

ALT5 Sigma will exhibit at booth #26 at the Dubai World Trade Centre from January 14-16, 2025.

What are the main platforms offered by ALT5 Sigma (ALTS)?

ALT5 Sigma offers two main platforms: ALT5 Pay, a cryptocurrency payment gateway, and ALT5 Prime, an electronic over-the-counter trading platform.

When was ALT5 Sigma (ALTS) included in the Russell Microcap Index?

ALT5 Sigma was included in the Russell Microcap Index as of June 28, 2024.

What payment options does ALT5 Pay (ALTS) offer to merchants?

ALT5 Pay allows merchants to accept cryptocurrency payments with options to automatically convert to fiat currency or receive payments in digital assets.